Attending the World Vaccine Congress East Conference in Wasington, DC? Stop by and say hi at booth S30 in the Start-Up Zone!
Attending the World Vaccine Congress East Conference in Wasington, DC? Stop by and say hi at booth S30 in the Start-Up Zone!
We are digitizing biology using novel computational methods and machine learning to give a full view of an individual’s immune system. By digitizing immune data, we accelerate discovery and development for therapies and diagnostics*. We envision a future where understanding the state of your immune system is part of everyday life.
Our history is rooted in work our founders pioneered at the Fred Hutch Institute for Cancer Research. There, they developed the foundational capabilities that enable the computational analysis of single-cell data leveraged worldwide. Through this work, they were able to foresee a fundamental shift in how we leverage single-cell data. To accelerate and realize the full impact of AI-driven analysis, we incubated at AI2 and raised our seed funding led by Madrona Ventures. We are proud of our Pacific Northwest roots and are excited to grow globally.
Rooted in science and technology, we are building our team from the ground up to be interdisciplinary at the core.
Ali is a physician fascinated by finding answers to the unknown. Prior to founding Ozette, he served as a consultant for McKinsey & Company and advisor to startups and venture capital firms. Ali completed his medical training at the University of Washington, where he continues to hold a part-time clinical appointment with the Fred Hutchinson Cancer Center. He has cultivated his curiosity into a lifelong passion for helping to deliver high quality science and medicine to the patients he serves.
Arthur is an experienced operator and investor who has served in senior management roles and led investments in a wide variety of companies. He is passionate about new applications for innovative technology. Prior to Ozette, Arthur was CFO for Turing AI, CFO/COO for the investment firm Ascent Capital Advisors, and previously worked at the investment banks Goldman Sachs, Nomura and Lehman Brothers. Arthur is a graduate of the Wharton School of the University of Pennsylvania.
Greg is a recognized leader and pioneer in the field of computational cytometry and single-cell methods development. He is passionate about technology and a champion for rigorous, high quality, reproducible and open science. He founded Ozette in 2020 with the guiding principle that scientific questions should push technology development. Prior to founding Ozette he served as a Senior Scientist at the Fred Hutchinson Cancer Research Center where he contributed to methods development and analysis of vaccine clinical trial data across HIV, TB, Malaria, and other disease areas. He graduated with a PhD from McGill University.
Evan is a globally recognized statistician pioneering new methods for the analysis of single-cell immune data. Prior to founding Ozette, he was a postdoctoral scholar and then data scientist at the Fred Hutchinson Cancer Center. In those roles, he worked on methods development for data generated by high-throughput single-cell instruments, and analyzed data generated by such instruments. Evan completed his PhD in statistics at the University of Washington.
Raphael is a pioneer of novel computational tools and methods to address today’s most pressing immunological problems through high-dimensional modeling and data integration. In 2018, he received the Mortimer Spiegelman Award, which honors a statistician below the age of 40 who has made outstanding contributions to health statistics. Raphael is a Full Professor of Biomedical Data Science at the University of Lausanne and the founding director of the Biomedical Data Science Center at the University Hospital of Lausanne. Before that, he was a Full Professor in the Vaccine and Infectious Disease Division at Fred Hutchinson Cancer Center, an affiliate Professor of statistics at the University of Washington, and scientific director of the Fred Hutch Translational Data Science Integrated Research Center. Dr. Gottardo’s current research interests center on the development of computational tools and new machine learning methods for analyzing high-dimensional single-cell data with applications to immunology, vaccine research, and immunotherapy. He has led a large number of projects funded by the National Institutes of Health, the Gates Foundation, and the Chan-Zuckerberg Initiative, among others.
Cherie is an established member and thought-leader of the cytometry community, where she’s driven impact for more than 25 years focusing on hematopathology, cell therapy, and biotech biomarker laboratories. As a biomarker scientist, her professional focus lies in understanding cellular interactions in complex diseases and the development of novel therapies. She is passionate about development of innovative single assays and computational analysis solutions to advance life changing therapeutic development. During her tenure at Amgen, Genentech, and small cell therapy companies, she championed the design and use of biomarkers in clinical trial design for early and late stage drug development in infectious, autoimmune, and oncology diseases. She has served as the co-chair of Flow Cytometry Action Committee of the American Association of Pharmaceutical Scientists (AAPS) and has co-authored over 50 publications and patents on topics specific to drug development such as instrument and assay validation, sample stability, and receptor occupancy, and biomarkers.
Corrie is most passionate about innovative health technologies which deliver impactful solutions for better patient outcomes. For more than 15 years, she has translated research into healthcare products. Prior to Ozette, Corrie led part of the health technologies portfolio at Global Health Labs, scaling and leading teams to take products from concept to delivery. She earned her PhD from the Department of Global Health at the University of Washington and a BA from the Department of Public Health at Johns Hopkins University.
* Data provided by Ozette is to be used for exploratory research purposes only, not to be used to make clinical decisions such as diagnosis, prevention, monitoring, treatment, alleviation of disease.